Skip to main content

Akebia Therapeutics: Q4 Earnings Snapshot

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Akebia Therapeutics Inc. (AKBA) on Thursday reported a loss of $12.2 million in its fourth quarter.

The Cambridge, Massachusetts-based company said it had a loss of 5 cents per share.

The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 3 cents per share.

The kidney disease treatment developer posted revenue of $57.6 million in the period, exceeding Street forecasts. Three analysts surveyed by Zacks expected $47.2 million.

For the year, the company reported that its loss narrowed to $5.3 million, or 2 cents per share. Revenue was reported as $236.2 million.

The company’s shares closed at $1.22. A year ago, they were trading at $1.82.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AKBA at https://www.zacks.com/ap/AKBA

One Tech Tip: What to know about flying with lithium ion portable battery chargers

Jetting off soon for summer travels? If you're planning on bringing an extra battery charger for your phone or other devices, be aware of the latest rules when taking one on a flight. Rechargeable lithium-ion portable battery chargers, also known as power banks, come in protective enclosures of various shapes and sizes. They're a handy and popular way for getting more juice when you're on the move. But after a spate of smoke or fire incidents, U.S. and international aviation authorities have issued new guidelines and airlines have tightened up rules for passengers. Here's a guide on flying with power banks.
Read Next Story

Related News

Knicks take 1-0 lead into game 2 against the Spurs

Beijing bans 4 New Zealand lawmakers from entering China because they visited Taiwan

Police warn families of Tiananmen crackdown dead not to visit graves on 37th anniversary